Literature DB >> 32606178

Implications of Low Serum Albumin as a Prognostic Factor of Long-term Outcomes in Patients With Breast Cancer.

Takaaki Fujii1, Shoko Tokuda2, Yuko Nakazawa2, Sasagu Kurozumi2, Sayaka Obayashi2, Reina Yajima2, Ken Shirabe2.   

Abstract

BACKGROUND/AIM: We examined the relationship between preoperative serum albumin levels and long-term outcomes in patients with breast cancer. PATIENTS AND METHODS: We retrospectively analyzed the records of 157 patients who underwent breast cancer surgery at a single institution. We divided the patients into those with <4.0 g/dl and those with ≥4.0 g/dl preoperative serum albumin.
RESULTS: The overall median follow-up period was 86.7 months. Among the 157 patients, 19 (12.1%) had decreased serum albumin levels preoperatively. A significant association with preoperative albumin levels was found only for patient age; however, we were unable to determine an association between preoperative albumin levels and various clinical features. The recurrence-free survival (p=0.030) and the overall survival (p=0.001) were both significantly shorter in patients with low albumin levels.
CONCLUSION: Low serum albumin levels were associated with poor prognosis, but not with poor-prognostic factors. Therefore, low albumin levels may reflect the tumor microenvironment in breast cancer. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Albumin; breast cancer; immunity; inflammation; prognosis

Mesh:

Substances:

Year:  2020        PMID: 32606178      PMCID: PMC7439858          DOI: 10.21873/invivo.12003

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss.

Authors:  D C McMillan; W S Watson; P O'Gorman; T Preston; H R Scott; C S McArdle
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

Review 2.  Cancer-associated malnutrition: an introduction.

Authors:  Maarten von Meyenfeldt
Journal:  Eur J Oncol Nurs       Date:  2005       Impact factor: 2.398

Review 3.  Assessment of nutritional status in cancer patients: widely neglected?

Authors:  G Delmore
Journal:  Support Care Cancer       Date:  1997-09       Impact factor: 3.603

Review 4.  Clinical Value of Nutritional Status in Cancer: What is its Impact and how it Affects Disease Progression and Prognosis?

Authors:  Maria Mantzorou; Antonios Koutelidakis; Stamatios Theocharis; Constantinos Giaginis
Journal:  Nutr Cancer       Date:  2017-10-30       Impact factor: 2.900

Review 5.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

Authors:  Campbell S D Roxburgh; Donald C McMillan
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

6.  Low preoperative serum albumin in colon cancer: a risk factor for poor outcome.

Authors:  Cheng-Chou Lai; Jeng-Fu You; Chien-Yuh Yeh; Jinn-Shiun Chen; Reiping Tang; Jeng-Yi Wang; Chih-Chien Chin
Journal:  Int J Colorectal Dis       Date:  2010-12-29       Impact factor: 2.571

7.  Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer.

Authors:  M D Barber; J A Ross; K C Fearon
Journal:  Nutr Cancer       Date:  1999       Impact factor: 2.900

8.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.

Authors:  Wanying Guo; Xin Lu; Qipeng Liu; Ting Zhang; Peng Li; Weiqiang Qiao; Miao Deng
Journal:  Cancer Med       Date:  2019-06-13       Impact factor: 4.452

9.  Impact of prognostic nutritional index on long-term outcomes in patients with breast cancer.

Authors:  Tomomi Mohri; Yasuhiko Mohri; Tsunehiko Shigemori; Kenji Takeuchi; Yoshiyuki Itoh; Toshio Kato
Journal:  World J Surg Oncol       Date:  2016-06-27       Impact factor: 2.754

10.  Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study.

Authors:  Tilman Kühn; Disorn Sookthai; Mirja E Graf; Ruth Schübel; Heinz Freisling; Theron Johnson; Verena Katzke; Rudolf Kaaks
Journal:  Br J Cancer       Date:  2017-09-12       Impact factor: 7.640

View more
  4 in total

1.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.

Authors:  Shigemasa Takamizawa; Tatsunori Shimoi; Natsuko Satomi-Tsushita; Shu Yazaki; Toshihiro Okuya; Yuki Kojima; Hitomi Sumiyoshi-Okuma; Tadaaki Nishikawa; Maki Tanioka; Kazuki Sudo; Emi Noguchi; Kan Yonemori
Journal:  BMC Cancer       Date:  2022-01-14       Impact factor: 4.430

3.  Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.

Authors:  Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

4.  The Prognostic Prediction Value of Systemic Inflammation Score and the Development of a Nomogram for Patients With Surgically Treated Breast Cancer.

Authors:  Zhang-Zan Huang; Xin Hua; Chen-Ge Song; Wen Xia; Xi-Wen Bi; Zhong-Yu Yuan; Zhen-Yu He; Jia-Jia Huang
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.